PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB‐CHOP (RCHOP) ± RADIOTHERAPY (RT) von Vassilakopoulos, T.P., Papageorgiou, S.G., Michail, M., Angelopoulou, M.K., Kourti, G., Kalpadakis, C., Kotsopoulou, M., Leonidopoulou, T., Konstantinidou, P., Kotsianidis, I., Boutsis, D., Michali, E., Sachanas, S., Terpos, E., Karianakis, G., Poziopoulos, C., Vadikolia, C., Pigaditou, A., Vrakidou, E., Anargyrou, K., Symeonidis, A., Stefanoudaki, E., Hadjiharissi, E., Papaioannou, M., Gainaru, G., Tsirogianni, M., Katodritou, E., Karmiris, T., Variami, E., Pappa, V., Dimopoulos, M., Roussou, P., Panayitidis, P., Konstantopoulos, K., Pangalis, G.A.

Volltext

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine von Miltiades, P, Lamprianidou, E, Vassilakopoulos, T P, Papageorgiou, S G, Galanopoulos, A G, Vakalopoulou, S, Garypidou, V, Papaioannou, M, Hadjiharissi, E, Pappa, V, Papadaki, H A, Spanoudakis, E, Tsatalas, K, Kotsianidis, I

Volltext